Open AccessAssociation between the Interleukin-1 Receptor Antagonist (IL1RN) Variable Number of Tandem Repeats (VNTR) Polymorphism and Lymphoma
Author(s) -
Hosna Sarani,
Behrouz Molashahi,
Mohsen Taheri,
Gholamreza Bahari,
Seyed Mahdi Hashemi,
Mohammad Hashemi,
Saeid Ghavami
Publication year - 2021
Publication title -
international journal of hematology- oncology and stem cell research.
Language(s) - English
Resource type - Journals
eISSN - 2008-3009
pISSN - 2008-2207
DOI - 10.18502/ijhoscr.v15i2.6039
Subject(s) - lymphoma , variable number tandem repeat , interleukin 1 receptor antagonist , immunology , medicine , allele , polymerase chain reaction , gastroenterology , biology , oncology , receptor antagonist , receptor , genetics , antagonist , gene
Lymphoma is a common hematopoietic cancer. Immunosuppression is one of the main risk factors for the development of lymphoma. The interleukin (IL)-1 receptor antagonist IL1RN, which binds to the IL-1 receptor, moderates a variety of immune responses related to IL-1. We aimed to assess the impact of IL1RN variable number of tandem repeats (VNTR) polymorphism on lymphoma risk in an Iranian population sample.
Materials and Methods: DNA was extracted from peripheral blood of 120 subjects with non-Hodgkin Lymphoma (NHL), 50 subjects with Hodgkin’s lymphoma (HL), and 186 unrelated healthy individuals. IL1RN VNTR polymorphism was detected using polymerase chain reaction.
Results: Our findings revealed that the IL1RN VNTR polymorphism was associated with protection against NHL (P≤0.001, OR: 0.30, 95% CI: 0.18-0.53). The IL1RN 2 allele significantly decreased the risk of NHL (p = 0.023, OR = 0.66, 95%CI = 0.46–0.93). In addition, we found that IL1RN 1/2 was associated with a lower risk of HL (p ≤0.001, OR = 0.24, 95%CI = 0.12–0.50).
Conclusion: Our results suggest that the presence of IL1RN VNTR polymorphism is associated with a decreased risk of lymphoma in an Iranian subpopulation in southeast Iran.